REGN

Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

06/23 08:00 am

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

06/22 06:36 pm

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

06/20 11:02 am

This Stock Is Up 58% This Year. Is It too Late to Buy?

06/17 02:30 am

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?

06/15 04:10 pm

Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

06/11 04:05 pm

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight

06/10 01:00 pm

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

06/09 08:22 pm

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

06/09 08:22 pm

Treg Cell-Based Therapies Clinical Trial Pipeline Appears Robust With 29+ Key Pharma Companies Actively Working in the Domain | DelveInsight

06/09 01:00 pm

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

06/03 08:00 am

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight

06/02 01:00 pm

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

05/28 04:00 pm

Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing

05/26 02:29 pm

CytomX Therapeutics to Present at Upcoming June Investor Conferences

05/21 08:00 am

Nvidia Earnings Could Decide Whether the AI Trade Still Holds

05/18 01:12 pm

Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight

05/18 01:00 pm

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

05/18 07:00 am

Why Is Regeneron Stock Sinking Monday?

05/18 06:28 am

Stock Market Today: Dow Jones, S&P 500 Futures Drop Following Drone Strike On UAE Nuclear Plant—Regeneron Pharma, NextNRG, ServiceNow In Focus

05/18 05:10 am

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

05/15 08:19 pm

UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

05/15 05:56 pm

Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.

05/08 09:30 am

Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

05/05 01:00 pm

Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight

04/30 01:00 pm

Oil Surges 6%, S&P 500 Wobbles Before Fed And Tech Earnings: Stock Market Today

04/29 12:34 pm

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

04/29 07:00 am

Regeneron Strikes Deal With Trump Administration To Cut Drug Prices

04/24 12:08 pm

FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program

04/23 10:04 pm

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

04/23 03:46 pm

Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsight

04/23 01:00 pm

FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat

04/23 11:02 am

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

04/22 05:30 pm

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée

04/22 05:30 pm

Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook

04/21 04:34 am

Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight

04/16 01:00 pm

Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight

04/15 01:00 pm

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

04/13 01:00 pm

Neomorph Announces Closing of $100 Million Series B Financing

04/13 09:00 am

Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs

04/13 08:38 am

Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants

04/13 01:00 am

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

04/13 01:00 am

Atopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage Pipeline

04/10 04:52 am

Atopic Dermatitis 68-Market Drug Forecast and Market Analysis Report 2023-2025 & 2025-2033

04/10 04:46 am

From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker

04/07 07:02 am

Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime

04/06 01:20 pm

AstraZeneca Strengthens Position In COPD Race With Successful Trials

03/27 08:46 am

Is Regeneron a Multimillionaire-Maker Stock?

03/27 08:30 am

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

03/24 02:00 am

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse

03/24 02:00 am